COVID-19 trials registries data warehouse

https://clinicaltrials.gov/show/NCT04708327

Dawn Louro

dawn.louro@staterbiopharma.com

2021-01-13

Recruiting

RCT

Randomized

Parallel

Blind label

multi-center

Treatment

inclusion criteria: age >18 at the time of informed consent able to understand and provide informed consent in either english or spanish at high risk for covid-19 disease progression by fulfilling at least one of the following criteria at screening: age ≥65 years has a diagnosis of chronic pulmonary disease requiring daily treatment (e.g. copd, chronic persistent asthma, cystic fibrosis, chronic bronchitis) has a diagnosis of chronic heart disease has a diagnosis of diabetes (type 1 or type 2) requiring oral therapy and/or insulin therapy has hypertension requiring at least one oral medication for treatment has a body mass index (bmi) of ≥33 kg/m2 has an immunocompromising disease (e.g. hiv infection with cd4 count < 200 cells/mm3) is immunocompromised due to daily treatment with ≥20 mg of prednisone or equivalent has received a solid organ transplant has any chronic condition that, in the opinion of the investigator, places the patient at increased risk for progression of covid-19 documentation of positive diagnostic test for sars-cov-2 (confirmed by pcr assay or other approved diagnostic test) performed with a sample from nares or saliva, collected within 7 days of the screening visit. is symptomatic for covid-19 for no more than 7 days prior to the screening visit has a who clinical progression scale (whob 2020) score of either '2' or '3' at screening and randomization has at least one of the following symptoms at the screening visit that are new in onset, or if present by history, has worsened during the 7 days prior to screening: · fever, chills, myalgia, arthralgia, headache, fatigue, cough, sore throat, nasal congestion, nausea, vomiting, diarrhea, anosmia or dysosmia, ageusia or dysgeusia if female of child-bearing potential, must agree to use of 2 forms of contraception from screening to end of the study. males must agree to use 2 forms of contraception from screening to the end of the study if their partners are of childbearing potential. acceptable methods of birth control which must be used together are: oral or injectable contraceptive and condom, or iud and condom, or diaphragm with spermicide and condom. agrees to participate in all in-person visits and remote or home visits as required by the protocol and to provide updated contact information, as necessary.

has a who clinical progression scale (whob 2020) score of '4' or higher at screening or enrollment previous hypersensitivity or allergic reactions to naltrexone women who are pregnant or lactating or expecting to become pregnant drugs of abuse screen positive for opiates patients with history of moderate to severe renal impairment (estimated creatinine clearance < 50 ml/min) or hepatic impairment (child-pugh c) serum alt or ast value > 3 times the uln at screening serum creatinine value > 2 times the uln at screening, or requires renal dialysis hematology results at screening showing any one of the following: wbc <2000 cells/mm3 or platelet count <100,000 cells/mm3 or hemoglobin <8.5 gm/dl currently receiving chronic daily opioid therapy use of tocilizumab or other immunomodulator therapy directed to treatment or prevention of covid-19 history of active substance abuse within the 2 years prior to screening participation in another clinical trial investigating a treatment for covid-19 currently hospitalized or under immediate consideration for hospitalization (for any medical reason) at the screening visit at screening, has new onset of dyspnea (shortness of breath) or, if previously diagnosed with a chronic lung condition, the severity of dyspnea has increased over patient's historical baseline condition (increased dyspnea should be present continually and not intermittent) measurement of oxygen saturation at screening is < 94% on ambient room air shares a household with a patient currently enrolled in this protocol patients who refuse biomarker blood draws

2

Cytocom, Inc.

18

100

United States

Mild disease at enrollment

1: Mild disease at enrollment

24

Proportion of patients who demonstrate progression of COVID-19 disease

None

Phase 1

[{"arm_notes": "45 mg ", "treatment_id": 855, "treatment_name": "Naltrexone", "treatment_type": "Central nervous system agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]